Comorbidities in ADHD children treated with methylphenidate: A database study

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Kraut, Angela A ^a   Langner, Ingo ^a   Lindemann, Christina ^a   Banaschewski, Tobias ^b   Petermann, Ulrike ^c   Petermann, Franz ^c   Mikolajczyk, Rafael T ^a,d   Garbe, Edeltraut ^a,c  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BREMEN   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD; COMORBIDITY; FEMALE; GERMANY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBROVASCULAR DISORDERS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DATABASES, FACTUAL; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MENTAL DISORDERS; METHYLPHENIDATE; PREVALENCE;

EID: 84871882490     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-11     Document Type: Article

References (54)

1. Rappley MD. Safety issues in the use of methylphenidate. An American perspective. Drug Saf 1997, 17:143-148.
2. Schubert I, Koster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int 2010, 107:615-621.
3. Sullivan SS. Narcolepsy in adolescents. Adolesc Med State Art Rev 2010, 21:542-555.
4. Schwabe U, Paffrath D. Arzneiverordnungs-Report '91 Akutelle Daten, Kosten, Trends und Kommentare 1990, Stuttgart, New York: Gustav Fischer Verlag.
5. Schwabe U, Paffrath D. Arzneiverordnungs-Report 2010 Aktuelle Daten, Kosten, Trends und Kommentare 2010, Berlin, Heidelberg: Springer.
6. Janhsen K. [Pillen für den Zappelphillipp]. GEK-Arzneimittelreport 2007. Auswertungsergebnisse der GEK-Daten aus den Jahren 2005-2006. Schriftenreihe zur Gesundheitsanalyse Volume 55 2007, 226-244. St. Augustin: Asgard-Verlag, Glaeske G, Janhsen K.
7. Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008, 64:311-317.
8. Schmidt-Troschke SO, Ostermann T, Melcher D, Schuster R, Erben CM, Matthiessen PF. The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions. Gesundheitswesen 2004, 66:387-392.
9. Vinker S, Vinker R, Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Investig 2006, 26:161-167.
10. Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009, 19:757-764.
11. Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, et al. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit / hyperactivity disorder in Germany. J Child Adolesc Psychopharmacol 2012, 22:307-14.
12. van den Ban E, Souverein P, Swaab H, van EH Heerdink R, Egberts T. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. J Child Adolesc Psychopharmacol 2010, 20:55-61.
13. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008, 42:24-31.
14. Merkel RL, Kuchibhatla A. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. Expert Opin Drug Saf 2009, 8:655-668.
15. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 2000, 3:243-267.
16. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010, 33:821-842.
17. Drug Safety and Risk Management Advisory Committee Meeting February 9-10, 2006 [http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202_00_TOC.htm].
18. Merkel RL. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. Expert Opin Drug Saf 2010, 9:917-935.
19. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 2008, 17:59-74.
20. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006, 354:1445-1448.
21. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991, 148:564-577.
22. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998, 59(Suppl 7):50-58.
23. Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents [http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Methylphenidate_31/WC500011184.pdf].
24. Press release. European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate-containing medicines in the EU [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Methylphenidate/human_referral_000100.jsp&mid=WC0b01ac0580024e9a].
25. Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 2008, 17:215-223.
26. Newcombe RG, Altman DG. Proportions and their differences. Statistics with confidence 2001, 45-56. Bristol: JW Arrowsmith Ltd, Altman DG, Newcombe RG, Altman DG.
27. Regio-Stat Regionalstatistischer Datenkatalog des Bundes und der Länder 2008 (unveröffentlichte Testversion) 2008, Statistische Ämter des Bundes und der Länder, Regio-Stat.
28. Schlack R, Holling H, Kurth BM, Huss M. The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007, 50:827-835.
29. Biederman J, Ball SW, Monuteaux MC, Mick E, Spencer TJ, McCreary M, et al. New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry 2008, 47:426-434.
30. Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rastam M, et al. Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):80-92.
31. Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am 1999, 46:915-27.
32. Bird HR, Gould MS, Staghezza-Jaramillo BM. The comorbidity of ADHD in a community sample of children aged 6 through 16 years. J Child Fam Stud 1994, 3:365-378.
33. Kadesjo B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001, 42:487-492.
34. Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents. Child Adolesc Psychiatry Ment Health 2008, 2:15.
35. Schmidt S, Petermann F. Developmental psychopathology: Attention Deficit Hyperactivity Disorder (ADHD). BMC Psychiatry 2009, 9:58.
36. Schmidt S, Brähler E, Petermann F, Koglin U. Komorbide Belastungen bei Jugendlichen und jungen Erwachsenen mit ADHS. Z Psychiatr Psychol Psychother 2012, 60:15-26.
37. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001, 40:147-158.
38. Biederman J, Monuteaux MC, Kendrick E, Klein KL, Faraone SV. The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. Arch Dis Child 2005, 90:1010-1015.
39. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder - first upgrade. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):7-30.
40. Preuss U, Ralston SJ, Baldursson G, Falissard B, Lorenzo MJ, Rodrigues PR, et al. Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006, 15(Suppl 1):4-14.
41. Ralston SJ, Lorenzo MJ. ADORE - Attention-Deficit Hyperactivity Disorder Observational Research in Europe. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):36-42.
42. Chronis-Tuscano A, Molina BS, Pelham WE, Applegate B, Dahlke A, Overmyer M, et al. Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2010, 67:1044-1051.
43. Taurines R, Schmitt J, Renner T, Conner AC, Warnke A, Romanos M. Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord 2010, 2:267-289.
44. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011, 365:1896-1904.
45. Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012, 345:e4627.
46. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008, 117:2407-2423.
47. Bass JL, Corwin M, Gozal D, Moore C, Nishida H, Parker S, et al. The effect of chronic or intermittent hypoxia on cognition in childhood: a review of the evidence. Pediatrics 2004, 114:805-816.
48. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007, 115:163-172.
49. Hauser P, Soler R, Brucker-Davis F, Weintraub BD. Thyroid hormones correlate with symptoms of hyperactivity but not inattention in attention deficit hyperactivity disorder. Psychoneuroendocrinology 1997, 22:107-114.
50. Spencer T, Biederman J, Wilens T, Guite J, Harding M. ADHD and thyroid abnormalities: a research note. J Child Psychol Psychiatry 1995, 36:879-885.
51. Schink T, Behr S, Garbe E. Externe Validierung von Verschreibungsdaten nichtsteroidaler Antirheumatika anhand des Arzneiverordnungsreports Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, abstract]. [http://www.egms.de/static/en/meetings/gmds2009/09gmds281.shtml.
52. Chen CY, Gerhard T, Winterstein AG. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19:187-195.
53. Radigan M, Lannon P, Roohan P, Gesten F. Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population. J Child Adolesc Psychopharmacol 2005, 15:44-56.
54. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011, 20:17-37.